It is a global medical technology company focused on developing and commercializing proprietary Vapotherm High Flow Therapy, a tool used to treat patients of all ages with respiratory distress.
High velocity therapy provides noninvasive ventilation support by supplying patients with high velocity heated, humidified and oxygenated air through a comfortable, small diameter nasal interface.
Providing high-rate therapy, Precision Flow systems are clinically approved alternatives to the current standard of care for the treatment of respiratory distress in the hospital setting and address many limitations.
As of September 30, 2021, more than 3.2 million patients have been treated with Precision Flow systems and has a global installed base of more than 34,500 equity units.
For more information https://vapotherm.com/